Clinical trial
A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With…
NCT00479427 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00479427 |
|---|---|
| Title | A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis |
| Official title | A Double-blind, Placebo Controlled Cross-over Study of the Effects of the CB2 Compound of GW842166 in Patients With Osteoarthritis |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | GW842166, Placebo |
| Enrollment | 1 |
| Start date | Jul 6, 2007 |
| Primary completion | Oct 9, 2007 |
| Completion | Oct 9, 2007 |
| First posted | May 28, 2007 |
| Last update posted | Jul 11, 2017 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: